Cambridge startup raises $110M for re-doseable gene therapies

Generation Bio has raised $110 million to support the company as it heads toward in-human trials.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.